Clinical Trials in Croatia

• Phase 3 Study of Telitacicept in Moderately to Severely Active Systemic Lupus Erythematosus (REMESLE-2) Not authorised
  2024-512716-21-00 Phase III Moderately to Severely Active Systemic Lupus Erythematosus Remegen Co. Ltd.
• Impact of time of alpelisib administration, concomitant fasting and low carbohydrate diet on alpelisib toxicity and efficacy; a pilot random… Not authorised
  2025-521008-22-00 Phase II metasatic breast cancer, hormon positive, her 2 negative Croatian Cooperative Group For Clinical Trial Research In Oncology
• A randomized, double-blind, placebo-controlled multicenter study to evaluate the effect of inclisiran on preventing major adverse cardiovasc… Unknown
  2022-502779-40-99 Phase III Primary prevention of atherosclerotic cardiovascular disease… Novartis Pharma AG
• A clinical study of MK-7240 for the treatment of ulcerative colitis (MK-7240-001) Unknown
  2025-523766-25-00 Phase III Ulcerative colitis Merck Sharp & Dohme LLC
• DALY II USA/MB-CART2019.1 for DLBCL Pending
  2023-508508-39-01 Phase II Relapsed/refractory diffuse large B cell lymphoma (R-R DLBCL… Miltenyi Biomedicine GmbH
• A Randomized, Multiple-Dose, Open-Label, Parallel-Group Study to Evaluate the Pharmacokinetic Profiles of LY03010 and the Relative Bioavaila… Pending
  2023-508981-13-00 Schizophrenia Geneora Pharma (Shijiazhuang) Co. Ltd.
• A research study on how well cagrilintide and CagriSema work in children and adolescents with excess body weight Pending
  2023-509176-42-00 Phase III/IV Obesity and T2D Novo Nordisk A/S
• ALLIC 2022 international clinical investigation for advanced management of childhood acute lymphoblastic leukemia Pending
  2024-513824-41-00 Phase IV Childhood non-mature-B Acute Lymphoblastic Leukemia Semmelweis University
• A clinical trial to learn about the long-term safety of FUB523 (zigakibart) in people with immunoglobulin A (IgA) nephropathy who have compl… Pending
  2024-519638-22-00 Phase III IgA nephropathy Novartis Pharma AG
• Open-label Extension of KarXT + KarX-EC for Agitation in Alzheimer’s Disease Pending
  2024-519994-20-00 Phase III Agitation Associated with Alzheimer’s Disease Bristol-Myers Squibb Services Unlimited Company
• A Study to Investigate GB-0895 Adjunctive Therapy in Adults and Adolescents with Severe Uncontrolled Asthma (SOLAIRIA-1) Pending
  2025-521950-41-00 Phase III severe uncontrolled asthma Generate Biomedicines Inc.
• A study to evaluate the long-term safety, tolerability, and efficacy of subcutaneous sonelokimab in participants with psoriatic arthritis (P… Pending
  2025-522471-28-00 Phase III psoriatic arthritis (PsA) MoonLake Immunotherapeutics AG
• A study to investigate the long-term safety, tolerability and efficacy of balinatunfib in participants with Crohn’s disease or ulcerative co… Pending
  2025-522511-42-00 Phase II Crohn's disease Sanofi-Aventis Recherche & Developpement
• A Phase 3, Long-Term Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of Zasocitinib in Subjects with Active Pso… Pending
  2025-522586-30-00 Phase III Psoriatic Arthritis Takeda Development Center Americas Inc.
• PODOMOUNT-Basket, a study to test whether BI 764198 helps adults and adolescents with different types of kidney disease Pending
  2025-523425-17-00 Phase II Proteinuric kidney diseases Boehringer Ingelheim Espana S.A.; Boehringer Ingelheim International GmbH
• A study to test whether different doses of BI 3000202 help people with systemic lupus erythematosus (SLE) Pending
  2025-523488-39-00 Phase II Systemic lupus erythematosus Boehringer Ingelheim Espana S.A.; Boehringer Ingelheim International GmbH
• A Phase 3 Study of Orelabrutinib in Patients with Primary Progressive Multiple Sclerosis Pending
  2025-524316-11-00 Phase III Primary Progressive Multiple Sclerosis (PPMS) Zenas Biopharma (USA) LLC
• AMAZE 8: A research study investigating how well the medicine NNC0487-0111 compared to semaglutide helps people with excess body weight and … Recruiting
  2024-520446-31-00 Phase III Participants with overweight or obesity, and type 2 diabetes Novo Nordisk A/S
• A Phase 2 Platform Study to Evaluate Therapies for Inflammatory Bowel Disease Recruiting
  2025-522001-38-00 Phase II Crohn’s Disease Mirador Therapeutics Inc.
• Long-term Efficacy and Safety Extension (LTE) Study of Barzolvolimab in Participants with Chronic Spontaneous Urticaria Recruiting
  2025-522878-36-00 Phase III Chronic Spontaneous Urticaria Celldex Therapeutics Inc.
• A study to learn if bimekizumab given in different ways is safe and moves similarly throughout the body over time in adults Recruiting
  2025-522782-30-00 Phase I (Other) CCI UCB Biopharma
• A study to find out if BI 764198 helps adults and adolescents with a kidney condition called focal segmental glomerulosclerosis (FSGS) Recruiting
  2025-522191-86-00 Phase III Focal segmental glomerulosclerosis Boehringer Ingelheim Espana S.A.; Boehringer Ingelheim International GmbH
• A Multi-Stage Study to Test a New Drug in Healthy Adult Volunteers, Then in Adults with Ulcerative Colitis Recruiting
  2025-522702-21-00 Phase II Ulcerative Colitis is a type of inflammatory bowel disease, … Xencor Inc.
• STOP-HAE: A Phase 3 Study of ADX-324 in HAE Recruiting
  2025-521352-38-00 Phase III Hereditary Angioedema Adarx Pharmaceuticals Inc.

Showing 1–24 of 266 trials